Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026
The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period. Market growth is largely driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine. Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, inadequate reimbursements of the esoteric test may restrict market growth to a certain extent. The esoteric testing market is segmented based on type, technology, end user and region.
“Infectious disease testing segment is expected to dominate the market during the forecast period and the genetic testing segment is also expected to grow at the highest CAGR during the forecast period.”
Based on product, the esoteric testing market is segmented into infectious disease testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. Infectious disease testing segment accounted the largest share of the esoteric testing market. The largest share of the segment is attributed to the increasing incidence of infectious diseases, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations. The genetic testing segment is expected to register the highest CAGR during the forecast period. The fastest growth of the genetic testing segment is attributed to the advancements in the sequencing technologies such as NGS and increasing awareness.
“CLIA segment to dominate the market during the forecast period.”
Based on technology, esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, real-time PCR, flow cytometry, DNA sequencing, and other technologies. CLIA accounted for the largest share of the esoteric testing market in 2020. The large share of this segment can be attributed to its advantages over other testing methods, such as high-performance levels, low detection limits, higher specificity, high signal intensity, and good precision.
“Independent & reference laboratories segment to dominate the market during the forecast period.”
Based on end user, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. Independent & reference laboratories account for the largest share of the esoteric testing market. The largest share is attributed to the high testing volumes. In addition, the ongoing automation, and digitalization of diagnostic laboratories, growing number of accredited laboratories, significant reimbursement coverage, and the competitive benefits offered by these providers are pushing the growth of the segment.
“North America will dominate the market during the forecast period.”
Geographically, the esoteric testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the esoteric testing market. The large share of the North American market can be attributed to the increasing per capita healthcare expenditure, presence of the leading market players, increasing use of rapid diagnostics, expanding geriatric population, and advancing precision medicine in the region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global esoteric testing market. It aims at estimating the size and future growth potential of the market across different segments, such as type, technology, end user and region. The report also analyzes factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total esoteric testing market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
“Infectious disease testing segment is expected to dominate the market during the forecast period and the genetic testing segment is also expected to grow at the highest CAGR during the forecast period.”
Based on product, the esoteric testing market is segmented into infectious disease testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. Infectious disease testing segment accounted the largest share of the esoteric testing market. The largest share of the segment is attributed to the increasing incidence of infectious diseases, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations. The genetic testing segment is expected to register the highest CAGR during the forecast period. The fastest growth of the genetic testing segment is attributed to the advancements in the sequencing technologies such as NGS and increasing awareness.
“CLIA segment to dominate the market during the forecast period.”
Based on technology, esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, real-time PCR, flow cytometry, DNA sequencing, and other technologies. CLIA accounted for the largest share of the esoteric testing market in 2020. The large share of this segment can be attributed to its advantages over other testing methods, such as high-performance levels, low detection limits, higher specificity, high signal intensity, and good precision.
“Independent & reference laboratories segment to dominate the market during the forecast period.”
Based on end user, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. Independent & reference laboratories account for the largest share of the esoteric testing market. The largest share is attributed to the high testing volumes. In addition, the ongoing automation, and digitalization of diagnostic laboratories, growing number of accredited laboratories, significant reimbursement coverage, and the competitive benefits offered by these providers are pushing the growth of the segment.
“North America will dominate the market during the forecast period.”
Geographically, the esoteric testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the esoteric testing market. The large share of the North American market can be attributed to the increasing per capita healthcare expenditure, presence of the leading market players, increasing use of rapid diagnostics, expanding geriatric population, and advancing precision medicine in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type - Tier 1: 48%, Tier 2: 40%, and Tier 3: 12%
- By Designation - C-level: 26%, D-level: 30%, and Others: 44%
- By Region - North America: 34%, Europe: 26%, Asia Pacific: 23%, and Rest of the World: 17%
- Labcorp (US)
- Quest Diagnostics (US)
- OPKO Health (US)
- H.U. Group Holdings, Inc. (Japan)
- Healius Limited (Australia)
- Sonic Healthcare (Australia)
- Mayo Foundation for Medical Education and Research (MFMER, US)
- Eurofins Scientific (Luxembourg)
- Stanford Clinical Pathology (US)
- Foundation Medicine (US)
- Kindstar Global (Beijing) Technology, Inc. (China)
- ARUP Laboratories (US)
- Georgia Esoteric & Molecular Laboratory, LLC (US)
- Thyrocare Technologies Ltd. (India)
- ACM Global Laboratories (US)
- BioAgilytix Labs (US)
- National Medical Services Inc. (NMS) (US)
- Baylor Esoteric and Molecular Laboratory (US)
- Cerba Xpert (Belgium)
- HealthQuest Esoterics (US)
- BUHLMANN Diagnostics Corp (BDC, US)
- BP Diagnostic Centre SDN BHD (Malaysia)
- Flow Health (US)
- Leo Labs, Inc. (India).
This report provides a detailed picture of the global esoteric testing market. It aims at estimating the size and future growth potential of the market across different segments, such as type, technology, end user and region. The report also analyzes factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total esoteric testing market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on esoteric testing services offered by the top 24 players in the esoteric testing market. The report analyses the esoteric testing market by type, technology, end user and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various esoteric testing services across key geographic regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the esoteric testing market.
- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the esoteric testing market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SEGMENTATION
1.3.1 MARKETS COVERED
FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP
APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF ESOTERIC TESTING SERVICES
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3.1 SECONDARY DATA
2.3.2 PRIMARY DATA
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT
2.8 COVID-19 ECONOMIC ASSESSMENT
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY
FIGURE 11 ESOTERIC TESTING MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 12 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2021 VS.
2026 (USD BILLION)
FIGURE 13 ESOTERIC TESTING MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE ESOTERIC TESTING MARKET
4 PREMIUM INSIGHTS
4.1 ESOTERIC TESTING MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2020)
FIGURE 16 ELISA SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
4.3 ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE ESOTERIC TESTING MARKET FROM 2021 TO 2026
4.4 ESOTERIC TESTING MARKET: REGIONAL MIX (2021–2026)
FIGURE 18 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
4.5 ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing geriatric population and the increasing prevalence of chronic and infectious diseases
FIGURE 21 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
TABLE 4 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES
5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and the early diagnosis of cancer
5.2.1.3 Advancements in esoteric tests for personalized medicine
5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine
5.2.1.5 Growing number of collaborations in the esoteric testing market
5.2.2 RESTRAINTS
5.2.2.1 Inadequate reimbursement
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging technologies in esoteric testing
5.2.3.2 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 COVID-19 HEALTH ASSESSMENT
FIGURE 24 COVID-19 GLOBAL PROPAGATION
5.4 IMPACT OF COVID-19 ON THE ESOTERIC TESTING MARKET
FIGURE 25 KEY PLAYERS: REVENUE IMPACT
5.5 REGULATORY OVERVIEW
TABLE 5 STRINGENCY OF REGULATIONS FOR CLINICAL LABORATORY ACCREDITATION, BY COUNTRY
5.5.1 NORTH AMERICA
5.5.1.1 US
5.5.1.2 Canada
5.5.2 EUROPE
TABLE 6 ACCREDITATION BODIES IN EUROPE
5.5.3 ASIA PACIFIC
5.5.3.1 Japan
5.5.3.2 India
5.5.3.3 China
5.6 TECHNOLOGY ANALYSIS
TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES
5.7 AVERAGE SELLING PRICE TREND
TABLE 8 AVERAGE SELLING PRICE OF ESOTERIC TESTS, 2021
5.8 PATENT ANALYSIS
FIGURE 26 LIST OF MAJOR PATENTS FOR THE ESOTERIC TESTING
FIGURE 27 REGIONAL ANALYSIS OF PATENTS GRANTED FOR THE ESOTERIC TESTING MARKET, 2015-2020
TABLE 9 INDICATIVE LIST OF ESOTERIC TESTING PATENTS
5.9 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.10 SUPPLY CHAIN ANALYSIS
FIGURE 29 DIRECT DISTRIBUTION IS THE PREFERRED STRATEGY FOR PROMINENT LABORATORIES
5.11 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET
FIGURE 30 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET
5.11.1 ROLE IN THE ECOSYSTEM
TABLE 10 ESOTERIC TESTING MARKET: ECOSYSTEM
FIGURE 31 KEY PLAYERS IN THE ESOTERIC TESTING MARKET ECOSYSTEM
5.12 DISRUPTIVE TECHNOLOGIES IN THE MARKET
FIGURE 32 DISRUPTIVE TECHNOLOGIES IN THE ESOTERIC TESTING MARKET
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 11 HIGH FRAGMENTATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
5.13.1 INTENSITY OF COMPETITIVE RIVALRY
5.13.2 BARGAINING POWER OF SUPPLIERS
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 THREAT OF NEW ENTRANTS
6 ESOTERIC TESTING MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 12 ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
6.2 INFECTIOUS DISEASE TESTING
6.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 13 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES
TABLE 14 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3 ENDOCRINOLOGY TESTING
6.3.1 INCREASING INCIDENCE OF DIABETES TO DRIVE THE ADOPTION
OF ESOTERIC TESTS
TABLE 15 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.4 ONCOLOGY TESTING
6.4.1 RISING PREVALENCE OF CANCER TO DRIVE THE
MARKET FOR ESOTERIC TESTING
TABLE 16 GLOBAL INCIDENCE OF CANCER IN MEN, 2020
TABLE 17 GLOBAL INCIDENCE OF CANCER IN WOMEN, 2020
TABLE 18 EXAMPLES OF ESOTERIC TESTS FOR THE DIAGNOSIS OF CANCER
TABLE 19 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.5 GENETIC TESTING
6.5.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH
TABLE 20 ESOTERIC GENETIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.6 TOXICOLOGY TESTING
6.6.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION HAVE INCREASED THE DEMAND FOR ESOTERIC TESTING
TABLE 21 ESOTERIC TOXICOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.7 IMMUNOLOGY TESTING
6.7.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
TABLE 22 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE
TABLE 23 EXAMPLES OF ESOTERIC TESTS AVAILABLE FOR IMMUNOLOGY TESTING
TABLE 24 ESOTERIC IMMUNOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.8 NEUROLOGY TESTING
6.8.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDER TO DRIVE MARKET GROWTH
TABLE 25 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS
TABLE 26 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.9 OTHER TESTING
TABLE 27 OTHER ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
7 ESOTERIC TESTING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 28 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
7.2 CHEMILUMINESCENCE IMMUNOASSAY
7.2.1 RISING GERIATRIC POPULATION TO AID MARKET GROWTH
TABLE 29 ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018–2026 (USD MILLION)
7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
7.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH
TABLE 30 EXAMPLES OF ESOTERIC ELISA TESTS
TABLE 31 ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018–2026 (USD MILLION)
7.4 MASS SPECTROMETRY
7.4.1 MASS SPECTROMETRY IS USED IN ENDOCRINE TESTING AND INFECTIOUS DISEASE DIAGNOSIS
TABLE 32 EXAMPLES OF ESOTERIC MASS SPECTROMETRY TESTS
TABLE 33 ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY REGION, 2018–2026 (USD MILLION)
7.5 REAL-TIME PCR
7.5.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO DRIVE MARKET GROWTH
TABLE 34 ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION, 2018–2026 (USD MILLION)
7.6 DNA SEQUENCING
7.6.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH
TABLE 35 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING
TABLE 36 ESOTERIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2018–2026 (USD MILLION)
7.7 FLOW CYTOMETRY
7.7.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET GROWTH
TABLE 37 ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 (USD MILLION)
7.8 OTHER TECHNOLOGIES
TABLE 38 ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2026 (USD MILLION)
8 ESOTERIC TESTING MARKET, BY END USER
8.1 INTRODUCTION
TABLE 39 ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
8.2 INDEPENDENT & REFERENCE LABORATORIES
8.2.1 INDEPENDENT & REFERENCE LABORATORIES ARE THE LARGEST END USERS OF ESOTERIC TESTS
TABLE 40 ESOTERIC TESTING MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY REGION, 2018–2026 (USD MILLION)
8.3 HOSPITAL-BASED LABORATORIES
8.3.1 HOSPITAL-BASED LABORATORIES ARE MORE ACCESSIBLE AND OFFER TEST RESULTS IN A SHORTER TIME PERIOD
TABLE 41 ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2018–2026 (USD MILLION)
9 ESOTERIC TESTING MARKET, BY REGION
9.1 INTRODUCTION
TABLE 42 ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT
TABLE 43 NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 46 NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominates the North American esoteric testing market
TABLE 47 US: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 48 US: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 49 US: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 50 US: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Lack of proper reimbursements for diagnostic tests to hamper the market growth
TABLE 51 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 52 CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 53 CANADA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3 EUROPE
TABLE 54 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 55 EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 56 EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 57 EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany held the largest share of the European esoteric testing market in 2020; this trend will continue in the forecast period
TABLE 58 GERMANY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 59 GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 60 GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 61 GERMANY: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Rising demand for early disease diagnosis to drive market growth
TABLE 62 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 63 FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 64 FRANCE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.3 ITALY
9.3.3.1 Rapidly growing geriatric population in Italy to favor market growth
TABLE 65 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 66 ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 67 ITALY: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.4 UK
9.3.4.1 The UK is the fastest-growing market for esoteric testing in Europe due to the favorable investment scenario in the country
TABLE 68 UK: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 69 UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 70 UK: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 High burden of chronic and infectious diseases in the country to drive the adoption of esoteric tests
TABLE 71 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 72 SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 73 SPAIN: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 74 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 75 ROE: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 76 ROE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 77 ROE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 78 ROE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 34 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT
TABLE 79 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 80 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 81 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 82 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Presence of a well-developed healthcare system to favor market growth in Japan
TABLE 83 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 84 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 85 JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 86 JAPAN: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.2 CHINA
9.4.2.1 China to register the highest growth rate in the esoteric testing market during the forecast period
TABLE 87 CHINA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 88 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 89 CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 90 CHINA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Improving healthcare system in the country to support market growth
TABLE 91 INDIA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 92 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 93 INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 94 INDIA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 95 ROAPAC: CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2040
TABLE 96 ROAPAC: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 97 ROAPAC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 98 ROAPAC: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 99 LATIN AMERICA: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 100 LATIN AMERICA: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 102 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 103 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 104 LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Brazil is the largest market for esoteric testing in Latin America
TABLE 105 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 106 BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 107 BRAZIL: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Growth in the private healthcare sector to propel market growth
TABLE 108 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 109 MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 110 MEXICO: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 111 ROLATAM: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 112 ROLATAM: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 113 ROLATAM: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 IMPROVEMENTS IN THE HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET FOR ESOTERIC TESTING IN THE MEA
TABLE 114 AFRICA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 115 MEA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 116 MEA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 117 MEA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY ESOTERIC TESTING LABORATORIES
10.3 REVENUE ANALYSIS
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN THE ESOTERIC TESTING MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 36 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2020
TABLE 118 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
10.5.1 STARS
10.5.2 PERVASIVE PLAYERS
10.5.3 EMERGING LEADERS
10.5.4 PARTICIPANTS
FIGURE 37 ESOTERIC TESTING MARKET (GLOBAL): COMPANY EVALUATION
QUADRANT, 2020
10.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 38 ESOTERIC TESTING MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS/SMES, 2020
10.7 COMPETITIVE BENCHMARKING
10.7.1 COMPANY TECHNOLOGY FOOTPRINT
10.7.2 COMPANY TESTING FOOTPRINT
10.7.3 COMPANY REGIONAL FOOTPRINT
10.7.4 COMPANY FOOTPRINT
10.8 COMPETITIVE SCENARIO AND TRENDS
10.8.1 DEALS
TABLE 119 DEALS, JANUARY 2018-MAY 2021
10.8.2 SERVICE LAUNCHES & APPROVALS
TABLE 120 SERVICE LAUNCHES & APPROVALS, JANUARY 2018-MAY 2021
10.8.3 OTHER DEVELOPMENTS
TABLE 121 OTHER DEVELOPMENTS, JANUARY 2018-MAY 2021
11 COMPANY PROFILES
11.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 LABCORP
TABLE 122 LABCORP: BUSINESS OVERVIEW
FIGURE 39 LABCORP: COMPANY SNAPSHOT (2020)
11.1.2 QUEST DIAGNOSTICS
TABLE 123 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 40 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2020)
11.1.3 OPKO HEALTH, INC.
FIGURE 41 OPKO HEALTH: COMPANY SNAPSHOT (2020)
11.1.4 H.U. GROUP HOLDINGS, INC.
TABLE 124 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW
FIGURE 42 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
11.1.5 HEALIUS LIMITED
TABLE 125 HEALIUS LIMITED: BUSINESS OVERVIEW
FIGURE 43 HEALIUS LIMITED: COMPANY SNAPSHOT (2020)
11.1.6 SONIC HEALTHCARE LIMITED
TABLE 126 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW
FIGURE 44 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2020)
11.1.7 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
FIGURE 45 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: COMPANY SNAPSHOT (2020)
11.1.8 EUROFINS SCIENTIFIC
TABLE 127 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
11.1.9 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY)
TABLE 128 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY): BUSINESS OVERVIEW
11.1.10 FOUNDATION MEDICINE, INC.
TABLE 129 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
11.1.11 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.
TABLE 130 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.: BUSINESS OVERVIEW
11.1.12 ARUP LABORATORIES
TABLE 131 ARUP LABORATORIES: BUSINESS OVERVIEW
11.1.13 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
TABLE 132 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW
11.1.14 THYROCARE TECHNOLOGIES LIMITED
TABLE 133 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW
FIGURE 47 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2020)
11.1.15 ACM GLOBAL LABORATORIES
TABLE 134 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 BIOAGILYTIX LABS
11.2.2 BP DIAGNOSTIC CENTRE SDN. BHD.
11.2.3 NMS LAB
11.2.4 BAYLOR ESOTERIC AND MOLECULAR LABORATORY
11.2.5 HEALTHQUEST ESOTERICS
11.2.6 CERBA XPERT
11.2.7 BUHLMANN DIAGNOSTICS CORP
11.2.8 LEO LABS, INC.
11.2.9 FLOW HEALTH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SEGMENTATION
1.3.1 MARKETS COVERED
FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP
APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF ESOTERIC TESTING SERVICES
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3.1 SECONDARY DATA
2.3.2 PRIMARY DATA
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT
2.8 COVID-19 ECONOMIC ASSESSMENT
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY
FIGURE 11 ESOTERIC TESTING MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 12 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2021 VS.
2026 (USD BILLION)
FIGURE 13 ESOTERIC TESTING MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE ESOTERIC TESTING MARKET
4 PREMIUM INSIGHTS
4.1 ESOTERIC TESTING MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2020)
FIGURE 16 ELISA SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
4.3 ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE ESOTERIC TESTING MARKET FROM 2021 TO 2026
4.4 ESOTERIC TESTING MARKET: REGIONAL MIX (2021–2026)
FIGURE 18 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
4.5 ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing geriatric population and the increasing prevalence of chronic and infectious diseases
FIGURE 21 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
TABLE 4 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES
5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and the early diagnosis of cancer
5.2.1.3 Advancements in esoteric tests for personalized medicine
5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine
5.2.1.5 Growing number of collaborations in the esoteric testing market
5.2.2 RESTRAINTS
5.2.2.1 Inadequate reimbursement
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging technologies in esoteric testing
5.2.3.2 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 COVID-19 HEALTH ASSESSMENT
FIGURE 24 COVID-19 GLOBAL PROPAGATION
5.4 IMPACT OF COVID-19 ON THE ESOTERIC TESTING MARKET
FIGURE 25 KEY PLAYERS: REVENUE IMPACT
5.5 REGULATORY OVERVIEW
TABLE 5 STRINGENCY OF REGULATIONS FOR CLINICAL LABORATORY ACCREDITATION, BY COUNTRY
5.5.1 NORTH AMERICA
5.5.1.1 US
5.5.1.2 Canada
5.5.2 EUROPE
TABLE 6 ACCREDITATION BODIES IN EUROPE
5.5.3 ASIA PACIFIC
5.5.3.1 Japan
5.5.3.2 India
5.5.3.3 China
5.6 TECHNOLOGY ANALYSIS
TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES
5.7 AVERAGE SELLING PRICE TREND
TABLE 8 AVERAGE SELLING PRICE OF ESOTERIC TESTS, 2021
5.8 PATENT ANALYSIS
FIGURE 26 LIST OF MAJOR PATENTS FOR THE ESOTERIC TESTING
FIGURE 27 REGIONAL ANALYSIS OF PATENTS GRANTED FOR THE ESOTERIC TESTING MARKET, 2015-2020
TABLE 9 INDICATIVE LIST OF ESOTERIC TESTING PATENTS
5.9 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.10 SUPPLY CHAIN ANALYSIS
FIGURE 29 DIRECT DISTRIBUTION IS THE PREFERRED STRATEGY FOR PROMINENT LABORATORIES
5.11 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET
FIGURE 30 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET
5.11.1 ROLE IN THE ECOSYSTEM
TABLE 10 ESOTERIC TESTING MARKET: ECOSYSTEM
FIGURE 31 KEY PLAYERS IN THE ESOTERIC TESTING MARKET ECOSYSTEM
5.12 DISRUPTIVE TECHNOLOGIES IN THE MARKET
FIGURE 32 DISRUPTIVE TECHNOLOGIES IN THE ESOTERIC TESTING MARKET
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 11 HIGH FRAGMENTATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
5.13.1 INTENSITY OF COMPETITIVE RIVALRY
5.13.2 BARGAINING POWER OF SUPPLIERS
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 THREAT OF NEW ENTRANTS
6 ESOTERIC TESTING MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 12 ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
6.2 INFECTIOUS DISEASE TESTING
6.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 13 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES
TABLE 14 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3 ENDOCRINOLOGY TESTING
6.3.1 INCREASING INCIDENCE OF DIABETES TO DRIVE THE ADOPTION
OF ESOTERIC TESTS
TABLE 15 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.4 ONCOLOGY TESTING
6.4.1 RISING PREVALENCE OF CANCER TO DRIVE THE
MARKET FOR ESOTERIC TESTING
TABLE 16 GLOBAL INCIDENCE OF CANCER IN MEN, 2020
TABLE 17 GLOBAL INCIDENCE OF CANCER IN WOMEN, 2020
TABLE 18 EXAMPLES OF ESOTERIC TESTS FOR THE DIAGNOSIS OF CANCER
TABLE 19 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.5 GENETIC TESTING
6.5.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH
TABLE 20 ESOTERIC GENETIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.6 TOXICOLOGY TESTING
6.6.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION HAVE INCREASED THE DEMAND FOR ESOTERIC TESTING
TABLE 21 ESOTERIC TOXICOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.7 IMMUNOLOGY TESTING
6.7.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
TABLE 22 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE
TABLE 23 EXAMPLES OF ESOTERIC TESTS AVAILABLE FOR IMMUNOLOGY TESTING
TABLE 24 ESOTERIC IMMUNOLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.8 NEUROLOGY TESTING
6.8.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDER TO DRIVE MARKET GROWTH
TABLE 25 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS
TABLE 26 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
6.9 OTHER TESTING
TABLE 27 OTHER ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
7 ESOTERIC TESTING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 28 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
7.2 CHEMILUMINESCENCE IMMUNOASSAY
7.2.1 RISING GERIATRIC POPULATION TO AID MARKET GROWTH
TABLE 29 ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018–2026 (USD MILLION)
7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
7.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH
TABLE 30 EXAMPLES OF ESOTERIC ELISA TESTS
TABLE 31 ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018–2026 (USD MILLION)
7.4 MASS SPECTROMETRY
7.4.1 MASS SPECTROMETRY IS USED IN ENDOCRINE TESTING AND INFECTIOUS DISEASE DIAGNOSIS
TABLE 32 EXAMPLES OF ESOTERIC MASS SPECTROMETRY TESTS
TABLE 33 ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY REGION, 2018–2026 (USD MILLION)
7.5 REAL-TIME PCR
7.5.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO DRIVE MARKET GROWTH
TABLE 34 ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION, 2018–2026 (USD MILLION)
7.6 DNA SEQUENCING
7.6.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH
TABLE 35 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING
TABLE 36 ESOTERIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2018–2026 (USD MILLION)
7.7 FLOW CYTOMETRY
7.7.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET GROWTH
TABLE 37 ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 (USD MILLION)
7.8 OTHER TECHNOLOGIES
TABLE 38 ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2026 (USD MILLION)
8 ESOTERIC TESTING MARKET, BY END USER
8.1 INTRODUCTION
TABLE 39 ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
8.2 INDEPENDENT & REFERENCE LABORATORIES
8.2.1 INDEPENDENT & REFERENCE LABORATORIES ARE THE LARGEST END USERS OF ESOTERIC TESTS
TABLE 40 ESOTERIC TESTING MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY REGION, 2018–2026 (USD MILLION)
8.3 HOSPITAL-BASED LABORATORIES
8.3.1 HOSPITAL-BASED LABORATORIES ARE MORE ACCESSIBLE AND OFFER TEST RESULTS IN A SHORTER TIME PERIOD
TABLE 41 ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2018–2026 (USD MILLION)
9 ESOTERIC TESTING MARKET, BY REGION
9.1 INTRODUCTION
TABLE 42 ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT
TABLE 43 NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 46 NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominates the North American esoteric testing market
TABLE 47 US: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 48 US: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 49 US: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 50 US: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Lack of proper reimbursements for diagnostic tests to hamper the market growth
TABLE 51 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 52 CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 53 CANADA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3 EUROPE
TABLE 54 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 55 EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 56 EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 57 EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany held the largest share of the European esoteric testing market in 2020; this trend will continue in the forecast period
TABLE 58 GERMANY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 59 GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 60 GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 61 GERMANY: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Rising demand for early disease diagnosis to drive market growth
TABLE 62 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 63 FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 64 FRANCE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.3 ITALY
9.3.3.1 Rapidly growing geriatric population in Italy to favor market growth
TABLE 65 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 66 ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 67 ITALY: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.4 UK
9.3.4.1 The UK is the fastest-growing market for esoteric testing in Europe due to the favorable investment scenario in the country
TABLE 68 UK: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 69 UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 70 UK: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 High burden of chronic and infectious diseases in the country to drive the adoption of esoteric tests
TABLE 71 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 72 SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 73 SPAIN: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 74 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 75 ROE: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 76 ROE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 77 ROE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 78 ROE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 34 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT
TABLE 79 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 80 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 81 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 82 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Presence of a well-developed healthcare system to favor market growth in Japan
TABLE 83 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 84 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 85 JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 86 JAPAN: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.2 CHINA
9.4.2.1 China to register the highest growth rate in the esoteric testing market during the forecast period
TABLE 87 CHINA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 88 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 89 CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 90 CHINA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Improving healthcare system in the country to support market growth
TABLE 91 INDIA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 92 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 93 INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 94 INDIA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 95 ROAPAC: CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2040
TABLE 96 ROAPAC: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 97 ROAPAC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 98 ROAPAC: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 99 LATIN AMERICA: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 100 LATIN AMERICA: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 102 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 103 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 104 LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Brazil is the largest market for esoteric testing in Latin America
TABLE 105 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 106 BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 107 BRAZIL: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Growth in the private healthcare sector to propel market growth
TABLE 108 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 109 MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 110 MEXICO: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 111 ROLATAM: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 112 ROLATAM: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 113 ROLATAM: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 IMPROVEMENTS IN THE HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET FOR ESOTERIC TESTING IN THE MEA
TABLE 114 AFRICA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 115 MEA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 116 MEA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 117 MEA: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY ESOTERIC TESTING LABORATORIES
10.3 REVENUE ANALYSIS
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN THE ESOTERIC TESTING MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 36 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2020
TABLE 118 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
10.5.1 STARS
10.5.2 PERVASIVE PLAYERS
10.5.3 EMERGING LEADERS
10.5.4 PARTICIPANTS
FIGURE 37 ESOTERIC TESTING MARKET (GLOBAL): COMPANY EVALUATION
QUADRANT, 2020
10.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 38 ESOTERIC TESTING MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS/SMES, 2020
10.7 COMPETITIVE BENCHMARKING
10.7.1 COMPANY TECHNOLOGY FOOTPRINT
10.7.2 COMPANY TESTING FOOTPRINT
10.7.3 COMPANY REGIONAL FOOTPRINT
10.7.4 COMPANY FOOTPRINT
10.8 COMPETITIVE SCENARIO AND TRENDS
10.8.1 DEALS
TABLE 119 DEALS, JANUARY 2018-MAY 2021
10.8.2 SERVICE LAUNCHES & APPROVALS
TABLE 120 SERVICE LAUNCHES & APPROVALS, JANUARY 2018-MAY 2021
10.8.3 OTHER DEVELOPMENTS
TABLE 121 OTHER DEVELOPMENTS, JANUARY 2018-MAY 2021
11 COMPANY PROFILES
11.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 LABCORP
TABLE 122 LABCORP: BUSINESS OVERVIEW
FIGURE 39 LABCORP: COMPANY SNAPSHOT (2020)
11.1.2 QUEST DIAGNOSTICS
TABLE 123 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 40 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2020)
11.1.3 OPKO HEALTH, INC.
FIGURE 41 OPKO HEALTH: COMPANY SNAPSHOT (2020)
11.1.4 H.U. GROUP HOLDINGS, INC.
TABLE 124 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW
FIGURE 42 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
11.1.5 HEALIUS LIMITED
TABLE 125 HEALIUS LIMITED: BUSINESS OVERVIEW
FIGURE 43 HEALIUS LIMITED: COMPANY SNAPSHOT (2020)
11.1.6 SONIC HEALTHCARE LIMITED
TABLE 126 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW
FIGURE 44 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2020)
11.1.7 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
FIGURE 45 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: COMPANY SNAPSHOT (2020)
11.1.8 EUROFINS SCIENTIFIC
TABLE 127 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
11.1.9 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY)
TABLE 128 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY): BUSINESS OVERVIEW
11.1.10 FOUNDATION MEDICINE, INC.
TABLE 129 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
11.1.11 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.
TABLE 130 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.: BUSINESS OVERVIEW
11.1.12 ARUP LABORATORIES
TABLE 131 ARUP LABORATORIES: BUSINESS OVERVIEW
11.1.13 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
TABLE 132 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW
11.1.14 THYROCARE TECHNOLOGIES LIMITED
TABLE 133 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW
FIGURE 47 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2020)
11.1.15 ACM GLOBAL LABORATORIES
TABLE 134 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 BIOAGILYTIX LABS
11.2.2 BP DIAGNOSTIC CENTRE SDN. BHD.
11.2.3 NMS LAB
11.2.4 BAYLOR ESOTERIC AND MOLECULAR LABORATORY
11.2.5 HEALTHQUEST ESOTERICS
11.2.6 CERBA XPERT
11.2.7 BUHLMANN DIAGNOSTICS CORP
11.2.8 LEO LABS, INC.
11.2.9 FLOW HEALTH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
